SEARCH

SEARCH BY CITATION

References

  • 1
    Arin MJ, Hunzelmann N. Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus – an update. Eur J Dermatol 2005; 15: 224230.
  • 2
    McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 28252833.
  • 3
    Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 9951001.
  • 4
    Reiser M, Wenger M, Nickenig C, Peter N, Metzner B, Pfreundschuh M. Serum levels and pharmacokinetic of ritu-ximab in Bi-weekly R-CHOP in elderly patients with DLBCL treated in the RI-COVER-60 trial. J Clin Oncol 2006; 24: 7537A.
  • 5
    Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 25722581.
  • 6
    Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Repopulation of B lymphocytes in peripheral blood following B lymphocyte depletion with ritu-ximab in rheumatoid arthritis. Arthritis Rheum 2006; 54: 613620.
  • 7
    Hertl M, Eming R, Borradori L. Rituximab (anti-CD20 monoclonal antibody) – ultimate or first choice in pemphigus? Dermatology 2007; 214: 275277.
  • 8
    Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. B-cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 25802590.
  • 9
    Edwards JCW, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Rev Immunol 2006; 6: 394403.
  • 10
    Ahmed AR, Spigelman Z, Cavacini LA, Poster MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 17721779.
  • 11
    Joly P, Mouquet H, Roujeau JC, D'In-can M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Dou-tre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede-Bohin E, Bernard P, Tron F, Hertl M, Musette P. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007; 357: 545552.
  • 12
    Borradori L, Lombardi T, Samson J, Gir-ardet C, Saurat JH, Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001; 137: 269272.
  • 13
    Arin MJ, Engert A, Krieg T, Hunzel-mann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br. J. Dermatol, 2005; 153: 620625.
  • 14
    Schmidt E, Hunzelmann N, Zillikens D, Bröcker EB, Goebeler M. Rituxi-mab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006; 31: 503508.
  • 15
    Eming R, Niedermeier A, Pfütze M, Jacobi A, Hertl M. Treating autoimmune bullous skin disorders with biologics. BoehnckeWH, RadekeH (Eds.): Bio-logics in General Medicine. Springer Science+Business Media, 2007.
  • 16
    Kasperkiewicz M, Zillikens D. Rituxi-mab (anti-CD20) zur Behandlung von bullösen Autoimmundermatosen. Hautarzt 2007; 58: 115121.
  • 17
    Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology 2007; 214: 310318.
  • 18
    Niedermeier A, Worl P, Barth S, Schuler G, Hertl M. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 2006; 16: 266270.
  • 19
    Goebeler M, Herzog S, Brocker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003; 149: 899901.
  • 20
    Schmidt E, Herzog S, Bröcker EB, Zillikens D, Goebeler M. Rituximab induced long-standing remission in a 14-year-old boy with treatment-resistant pemphigus vulgaris. Br J Dermatol 2005; 153: 449451.
  • 21
    Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Serological changes following B cell depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 21462154.
  • 22
    Schmidt E, Benoit S, Bröcker E-B, Zil-likens D, Goebeler M. Successful treatment of recalcitrant epidermolysis bullosa acquisita with rituximab. Arch Dermatol 2006; 142: 4750.
  • 23
    Niedermeier A. Eming R, Pfütze M, Neumann CR, Happel C, Reich K, Hertl M. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 2007; 143: 192198.
  • 24
    Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156: 352356.
  • 25
    Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D. Treatment of severe pemphigus with protein A immunoad-sorption, rituximab and intravenous im-munoglobulins. Br J Dermatol 2007; doi: DOI: 10.1111/j.1365-2133.2007.08358.x.
  • 26
    Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003; 148: 602603.
  • 27
    Pfütze M, Eming R, Niedermeier A, U Kuhlmann , Hoyer J, Hertl M. Both immunoadsorption and rituximab induce prolonged clinical responses in pemphigus vulgaris. (einger. z. Publ.).
  • 28
    Rituxan warning. FDA Consum. 2007; 41: 3.
  • 29
    Pfütze M, Niedermeier A, Hertl M, Eming R. Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus. Eur J Dermatol. 2007; 17: 411.